COVID 19

DXB: Making Strong Progress on “Main Bet,” Side Bet #2 Paused

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB) released its half year report last Thursday, updating investors on ethics approvals for its Phase III clinical trial for FSGS (a rare kidney disease) and closing in on important milestones for TWO of its Phase III COVID-19 studies.

DXB announces approval for Phase III COVID-19 trials

On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.

CM8 Signs Vital European Sales Agreement for High Demand Healthcare Products

Crowd Media Holdings Limited (ASX:CM8 | FWB:CM3) and VITAL have joined together with a two-year exclusive and binding Marketing Services Agreement to market and sell key VITAL portfolio brands and products into the European market

Could a NASDAQ Listing Put MYQ on the US Health & Fitness Map?

Software as a service (SaaS) solution provider MyFiziq Limited (ASX: MYQ) is set for a secondary listing on the NASDAQ Capital Market.

ASX Listed Tech Stock’s Health App Can Help Fight Obesity and COVID-19

MyFiziq's (ASX: MYQ) technology allows for the easy collection and comparison of measurements for clothing, weight management, athletic goals, and the medical field treating illnesses such as diabetes and obesity..

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.